Michael Barbella, Managing Editor06.21.24
A study is underway to evaluate O2matic's solution for optimizing oxygen treatment.
Adit Ginde, M.D., professor of Emergency Medicine and Anesthesiology at the University of Colorado School of Medicine, is evaluating the efficacy of automatic oxygen therapy through the SAVE-O2 AI study. The 300-patient multi-center randomized trial is funded by the U.S. Department of Defense through the Medical Technology Enterprise Consortium (MTEC) to further oxygen research using autonomous solutions. Published results are expected in 2026.
The SAVE-O2 trial focuses on redefining oxygen requirements in critically ill trauma patients through targeting normoxemia. Preliminary results from analyzing data from approximately 12,000 randomized patients have unveiled promising outcomes, suggesting that manually targeting normoxemia successfully reduces hyperoxemia without increasing hypoxemia, resulting in lower mortality rates, shortened hospital stays, and decreased supplemental oxygen requirements.
O2matic's PRO 100 "oxygen robot" optimizes oxygen treatment by regulating the supply based on a continuous measurement of the blood oxygen content. O2matic PRO 100 performs individually tailored monitoring and regulation of oxygen dosage using an advanced algorithm and input from a pulse oximeter. A sensor (pulse oximeter) measures the patient’s blood oxygen level, and PRO 100’s advanced software automatically adjusts the dose of oxygen accordingly. At the same time, the PRO 100 monitors the patient’s vital parameters, pulse and SpO2, and sounds an alarm if the patient's condition requires attention.
The advantages of automatic oxygen treatment, according to O2matic:
Ginde presented initial results at the Military Health System Research Symposium in 2023, earning his team the distinguished recognition of Outstanding Research Accomplishment. Their advancements in oxygen therapy protocols have already begun to influence guidelines, with updates to 10 relevant Joint Trauma System guidelines.
“We at O2matic are deeply honored to be part of this study and eagerly anticipate the potential impact of our technology on acute and trauma patients,” O2matic CEO Arnt Lund stated. “We are also grateful to the IDE sponsor for this study, IDTS Medical Inc. and its CEO, Mario Nozzarella, who guided us through the U.S. Food and Drug Administration Investigational Device Exemption process and received our final (non-conditional) letter regarding the submission G230325/A001 with a strong sense of urgency.”
O2matic is a Danish medical device company developing next-generation oxygen therapy and monitoring technologies.
Adit Ginde, M.D., professor of Emergency Medicine and Anesthesiology at the University of Colorado School of Medicine, is evaluating the efficacy of automatic oxygen therapy through the SAVE-O2 AI study. The 300-patient multi-center randomized trial is funded by the U.S. Department of Defense through the Medical Technology Enterprise Consortium (MTEC) to further oxygen research using autonomous solutions. Published results are expected in 2026.
The SAVE-O2 trial focuses on redefining oxygen requirements in critically ill trauma patients through targeting normoxemia. Preliminary results from analyzing data from approximately 12,000 randomized patients have unveiled promising outcomes, suggesting that manually targeting normoxemia successfully reduces hyperoxemia without increasing hypoxemia, resulting in lower mortality rates, shortened hospital stays, and decreased supplemental oxygen requirements.
O2matic's PRO 100 "oxygen robot" optimizes oxygen treatment by regulating the supply based on a continuous measurement of the blood oxygen content. O2matic PRO 100 performs individually tailored monitoring and regulation of oxygen dosage using an advanced algorithm and input from a pulse oximeter. A sensor (pulse oximeter) measures the patient’s blood oxygen level, and PRO 100’s advanced software automatically adjusts the dose of oxygen accordingly. At the same time, the PRO 100 monitors the patient’s vital parameters, pulse and SpO2, and sounds an alarm if the patient's condition requires attention.
The advantages of automatic oxygen treatment, according to O2matic:
- Reduced time in hyperoxia (56%) and time in severe hypoxemia (SpO2 < 85%) by 93%.
- Significantly better at keeping patients in the correct oxygen range than manual treatment.
- Increased walking distances by 98% and halved shortness of breath in patients with severe COPD on the Borg scale from 8 to 4 (12).
- Close and continuous monitoring of oxygen treatment.
- Alarm function that notifies of changes in the patient’s condition.
- Shorter hospital stays and faster weaning, which provide clinical and health-economic benefits.
Ginde presented initial results at the Military Health System Research Symposium in 2023, earning his team the distinguished recognition of Outstanding Research Accomplishment. Their advancements in oxygen therapy protocols have already begun to influence guidelines, with updates to 10 relevant Joint Trauma System guidelines.
“We at O2matic are deeply honored to be part of this study and eagerly anticipate the potential impact of our technology on acute and trauma patients,” O2matic CEO Arnt Lund stated. “We are also grateful to the IDE sponsor for this study, IDTS Medical Inc. and its CEO, Mario Nozzarella, who guided us through the U.S. Food and Drug Administration Investigational Device Exemption process and received our final (non-conditional) letter regarding the submission G230325/A001 with a strong sense of urgency.”
O2matic is a Danish medical device company developing next-generation oxygen therapy and monitoring technologies.